Reports on pregnancy outcomes following ofatumumab treatment can help health care professionals make better informed decisions when managing women of childbearing age living with MS. Maternal and ...

MILAN — Subcutaneous administration of anti-CD20 monoclonal antibody therapy offers ongoing clinical efficacy in the management of patients with relapsing and primary progressive multiple sclerosis ...

Ofatumumab is more effective than teriflunomide for relapsing multiple sclerosis across subgroups. HealthDay News — For patients with relapsing multiple sclerosis (RMS), ofatumumab is more effective ...

Please provide your email address to receive an email when new articles are posted on . DENVER — Early initiation of treatment with ofatumumab showed sustained benefit to those with treatment-naïve ...

MINNEAPOLIS – For people with relapsing-remitting multiple sclerosis (MS), a new study has found that the drug ofatumumab is more effective than teriflunomide at helping people across racial and ...

A new monoclonal antibody treatment called Kesimpta (ofatumumab) appears to improve on an older drug in pushing multiple sclerosis (MS) into remission, a new trial shows. Funded by Kesimpta's maker, ...

Breastfeeding by women with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder who are taking monoclonal antibodies (mAbs) appears to be safe for infants, new research confirmed. "Most ...